Agarwal, Sameer; Pethani, Jignesh P.; Shah, Hardik A.; Vyas, Vismit; Sasane, Santosh; Bhavsar, Harsh; Bandyopadhyay, Debdutta; Giri, Poonam; Viswanathan, Kasinath; Jain, Mukul R.; Sharma, Rajiv published the artcile< Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor>, SDS of cas: 1003-32-3, the main research area is oral bioavailable NLRP3 inflammasome inhibitor synthesis alkenyl sulfonylurea; Acute respiratory distress syndrome (ARDS); Coronavirus disease 2019 (COVID-19); Inflammation; Interleukin-1β (IL-1β); NLRP3; NLRP3 inflammasome; Sulfonylurea.
NLRP3 inflammasome mediated release of interleukin-1β (IL-1β) has been implicated in various diseases, including COVID-19. In this study, rationally designed alkenyl sulfonylurea derivatives were identified as novel, potent and orally bioavailable NLRP3 inhibitors. Compound 7 (I) was found to be potent (IL-1β IC50 = 35 nM; IL-18 IC50 = 33 nM) and selective NLRP3 inflammasome inhibitor with excellent pharmacokinetic profile having oral bioavailability of 99% in mice.
Bioorganic & Medicinal Chemistry Letters published new progress about Acute respiratory distress syndrome. 1003-32-3 belongs to class thiazole, and the molecular formula is C4H3NOS, SDS of cas: 1003-32-3.
Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica